Eli Lilly and Co (LLY.US) weight loss drug breakthrough! Research shows that tirzepatide can significantly reduce the risk of heart failure.
eli lilly and co's flagship weight loss drug Zepbound and diabetes treatment drug Mounjaro's active ingredient Tirzepatide can significantly reduce the risk of worsening heart failure in obese adults with heart failure with preserved ejection fraction (HFpEF).
Market Chatter: Eli Lilly, Novo Nordisk Press Employers to Cover the Cost of Weight-Loss Drugs
Eli Lilly's Muvalaplin Shows Positive Phase 2 Results in Reducing Heart Disease Risk Factor
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them -- WSJ
Express News | Eli Lilly and Co announced the detailed results of the SURMOUNT-1 study.
Eli Lilly and Co (LLY.US) potential groundbreaking oral small molecule significantly reduces cardiovascular events in high-risk adults with elevated Lp(a) levels.
Ruth Gimeno, Vice President of the Diabetes and Metabolic Research Group at eli lilly and co, stated: "We are pleased to see these promising results and look forward to further exploring the next steps for muvalaplin."